Hani Al-Hashmi, MD, EMSHA, LSSBBP

🎇𝐖𝐞 𝐚𝐭 Conglomerate Healthcare 𝐰𝐨𝐮𝐥𝐝 𝐥𝐢𝐤𝐞 𝐭𝐨 𝐞𝐱𝐭𝐞𝐧𝐝 𝐨𝐮𝐫 𝐡𝐞𝐚𝐫𝐭𝐟𝐞𝐥𝐭 𝐜𝐨𝐧𝐠𝐫𝐚𝐭𝐮𝐥𝐚𝐭𝐢𝐨𝐧𝐬 𝐭𝐨 King Faisal Specialist Hospital and Research Center (𝐊𝐅𝐒𝐇𝐑𝐂) 𝐟𝐨𝐫 𝐛𝐞𝐢𝐧𝐠 𝐡𝐨𝐧𝐨𝐫𝐞𝐝 𝐰𝐢𝐭𝐡 𝐭𝐡𝐞 2024 𝐓𝐞𝐜𝐡 𝐈𝐦𝐩𝐚𝐜𝐭 𝐀𝐰𝐚𝐫𝐝 𝐛𝐲 𝐭𝐡𝐞 𝐕𝐚𝐥𝐮𝐞-𝐁𝐚𝐬𝐞𝐝 𝐇𝐞𝐚𝐥𝐭𝐡 𝐂𝐚𝐫𝐞 𝐂𝐞𝐧𝐭𝐫𝐞 𝐄𝐮𝐫𝐨𝐩𝐞🎇 KFSHRC's HHD program addresses the unique needs of #kidneypatients, particularly those with advanced medical conditions, disabilities, and mobility challenges. By providing comprehensive care directly in patients' homes, the initiative has significantly improved #patientoutcomes, including reduced #emergencyroom visits, lower #hospitaladmissions, and decreased re-hospitalization rates. This patient-centric approach not only enhances the quality of life for these individuals but also demonstrates a substantial reduction in the management burden of chronic kidney disease-related conditions​. Moreover, KFSHRC's consistent ranking as the top healthcare institution in #SaudiArabia and among the world's top 250 hospitals highlights their commitment to excellence in healthcare and innovation. Their strategic partnerships and advanced medical research further solidify their role as a leader in the #globalhealthcarelandscape​. #healthcareexcellence #patientcare #innovationinhealthcare #KFSHRC #techimpactaward #healthcareinnovation #medicalresearch #healthcareleadership #middleeasthealthcare #globalhealth #advancedmedicalcare #homehemodialysis #patientcentriccare

٣

Join our upcoming webinar and discover how clinical trials are revolutionizing patient care and paving the way for a healthier future.

١٢

💰“Why pharmacoeconomics?”💰 In a world where high need for healthcare services exists and limited resources remain a barrier, pharmacoeconomics are indeed needed to recruit money where it is inevitably most-needed to fulfill Egypt’s 2030 vision. Contributing individually and collectively through their profession, pharmacoeconomists are dedicated to fairly advocate for policies and studies to safeguard the welfare of patients. High healthcare need is created due to the fact that: * elderly population numbers are increasing * new diseases emerge day by day * public health awareness is rising * the trend is currently preventive towards disease not just reactive Limited resources exist due to: * relatively less professional experts and hospitals * excessive legislation and approvals that delay new interventions emergence * food,water and shelter necessities in underdeveloped countries tend to divert the attention needed for healthcare sector ____________________ —This content is created by IVPN Student Rana Bedair —IVPN pharmacoeconomics Leader Dr Hend M. El Tayebi, PhD, MSc, MBA, BCPS —IVPN Founder& President Dr Osama Tabbara #The_Pharmacoeconomics_Series #IVPN_Pharmacoeconomics #1st_Scientific_Series

١٦

٢ تعليق

The revenue in the Pharmaceuticals market in Saudi Arabia is estimated to reach US$5.56bn by the year 2024. Among the various markets, the largest market share belongs to Oncology Drugs, with a projected market volume of US$1.08bn in 2024. It is expected that the revenue will witness a compound annual growth rate (CAGR 2024-2028) of 6.08%, resulting in a market volume of US$7.04bn by the year 2028. In comparison to other countries around worldwide, United States is expected to generate the highest revenue, amounting to US$636.90bn in 2024. Saudi Arabia is experiencing a surge in the demand for pharmaceuticals as the government invests heavily in healthcare infrastructure. The projected revenue for the Pharmaceuticals market in 2024 is estimated to reach US$1,966.00m. Among the various markets, Oncology Drugs is expected to be the largest, with a projected market volume of US$382.40m in 2024. Looking ahead, the revenue is anticipated to demonstrate a Compound Annual Growth Rate (CAGR 2024-2028) of 7.70%, resulting in a market volume of US$2,645.00m by 2028. When compared globally, United States is expected to generate the highest revenue, amounting to US$636.90bn in 2024. The United Arab Emirates, being a significant player in the Pharmaceuticals market, is expected to contribute to this growth. The Pharmaceuticals market in Egypt is forecasted to achieve a revenue of US$1,449.00m in 2024. among the various markets, the largest market share belongs to Oncology Drugs, which is projected to reach a market volume of US$240.00m in the same year. Looking ahead, the market is expected to witness a steady annual growth rate (CAGR 2024-2028) of 7.68%, resulting in a market volume of US$1,948.00m by 2028. When compared globally, United States is anticipated to generate the highest revenue, amounting to a staggering US$636.90bn in 2024. Egypt's pharmaceutical market is experiencing a surge in demand for generic drugs due to their affordability and accessibility.

٣

١ تعليق واحد

What is the role of pharmacist as clinical benefit evaluator? 🤔 Dr. Amal Al-Najjar who is the Director of Clinical Benefit Evaluation Department, Center of Health Technology Assessment at MOH will answer our question during #Inspiring_speech at #IHOP6 ✨

٦٠

٢ تعليق

As vendors to Novartis Saudi Arabia | نوفارتس السعودية and IQVIA Middle East and Africa, we are happy to share the findings of our #RWE study with the medical community. This study was led by Dr. Ibrahim Al-Homod, MD,FACP, consultant internal medicine, esteemed Rheumatologist and Chairman of the postgraduate department at King Fahad Medical City - KFMC. We determined the “treatment retention rate” to check the percentage of patients who continued to use the drug over 6 and 12 months. The percentage of treatment retention after 6 months was 100%. Considering the patients who started secukinumab 12 months or more prior to the study cutoff date (December 2022), the 12-month retention rate was 85%. DAPSA score showed a statistically significant decrease among those who received secukinumab alone by approximately 20.9 and 21.4 (p values < 0.001 for each) compared to 23.7 and 25.9 in combination with MTX (p-value = 0.012 & 0.006, respectively) after 6 and 12 months of treatment, respectively, compared to the baseline. read more (link in the comments)!

٤٤

٣ تعليق

Unlock “The jigsaw of value approaches for innovative pharmaceutical products” with Dr. Hussain Al-Omar (Associate Professor of Pharmacoeconomics at King Saud University) Join us at MENAHTA Forum 2024 as we delve into the broad spectrum of health technology assessments. From understanding HTA principles to exploring diverse modalities and cost-containment strategies, it's a journey you won't want to miss. Register now and be part of the conversation shaping the future of healthcare! Follow MENAHTA Forum on LinkedIn for more updates! #MENAHTAForum #Pharmaexpert #MENAHTAForum2024 #Agenda #Pharmacoeconomics

٧

Hi there, You are invited to a Zoom meeting.  When: Apr 25, 2024 06:00 PM Riyadh Register in advance for this meeting: https://lnkd.in/dX7XF94y After registering, you will receive a confirmation email containing information about joining the meeting.

٣٢

Hi there, You are invited to a Zoom meeting.  When: Apr 25, 2024 06:00 PM Riyadh Register in advance for this meeting: https://lnkd.in/dX7XF94y After registering, you will receive a confirmation email containing information about joining the meeting.

٧

📺 Just finished watching an insightful interview with the legend Khaled Elahmad! 💫 I've been following and connecting with Khaled Elahmad for a while now, and I couldn't agree more with him on the importance of leveraging LinkedIn effectively and building your personal brand. If you're not doing this, you're missing out on limitless opportunities! 💼 The interview, conducted in Arabic but subtitled in English, Khaled Al Ahmed, an expert in personal branding and career guidance, shared invaluable insights on how to enhance your job prospects on LinkedIn. 🎙️ 💡According to Al Ahmed, "Applying for a job is not just about clicking a button and waiting. It's an art that requires effort and the right tools, and LinkedIn is one of the most important avenues." 🛠️The problem is that 90% of people aren't using LinkedIn correctly. ✅So how do you build an engaging LinkedIn profile, even if you don't have much professional experience? ✅Why should you prioritize LinkedIn over other social platforms? ✅How do you engage effectively, and what are the common mistakes to avoid? 🤔 💬Don't miss out on this opportunity to level up your LinkedIn game! 🎧 Tune in to the podcast episode to learn more. 🔥 #PersonalBranding #LinkedIn #CareerAdvice #futureofwork #ProfessionalDevelopment

١٤

𝐇𝐞𝐚𝐥𝐭𝐡 𝐒𝐞𝐜𝐭𝐨𝐫 𝐓𝐫𝐚𝐧𝐬𝐟𝐨𝐫𝐦𝐚𝐭𝐢𝐨𝐧 𝐏𝐫𝐨𝐠𝐫𝐚𝐦 (𝐇𝐒𝐓𝐏) 🔲 The Saudi Government aims to ensure the provision of comprehensive, integrated healthcare to all the population in a manner that is fair, accessible and organized. 🔲 As part of #SaudiVision2030, the launch of the #𝐇𝐒𝐓𝐏 reinforces this human dimension, emphasizing continuity, development of the health system in general and enhanced quality of care and services provided. 🔲 The #𝐇𝐒𝐓𝐏 is transforming the Kingdom's #healthcare system to be more #comprehensive, #effective, and #integrated than ever before. 🔲 This enhanced system prioritizes innovation, financial sustainability, and disease prevention while improving access to healthcare. It also focuses on expanding e-health services and digital solutions, improving the quality of care, and adhering to international standards. 🔲 The program will also work to complete the implementation of the four strategic objectives set out for the Kingdom’s health system, having transitioned from the National #Transformation Program to the 𝐇𝐒𝐓𝐏, as well as initiatives associated with it. 🎯 𝐓𝐡𝐞 𝐬𝐭𝐫𝐚𝐭𝐞𝐠𝐢𝐜 𝐨𝐛𝐣𝐞𝐜𝐭𝐢𝐯𝐞𝐬 𝐚𝐫𝐞:  1️⃣ Facilitating access to health services 2️⃣ Improving the quality and efficiency of services 3️⃣ Promoting prevention of health risks, 4️⃣ Enhancing traffic safety King Faisal Specialist Hospital and Research Center Ministry of Health Saudi Arabia King Saud bin Abdulaziz University for Health Sciences King Abdullah Medical City, Mecca Prince Sultan Military Medical City King Fahad Medical City - KFMC King Fahad Specialist Hospital Dammam King Fahad Armed Forces Hospital King Khaled Eye Specialist Hospital (KKESH) King Khaled Hospital Saudi German Health Dr. Sulaiman AL Habib Medical Group Prince Mohammed bin Abdulaziz Medical City King Saud Medical City Saudi Commission for Health Specialties (SCFHS) Prince Sultan Military College of Health Sciences - Al Dhahran Ministry of National Guard Health Affairs (MNGHA) King Abdullah bin Abdulaziz University Hospital King Fahad Specialist Hospital Dammam Dallah Hospital SFDA - هيئة الغذاء والدواء Security Forces Hospital - Riyadh Security Forces Hospital Program - Dammam Security Forces Hospital - Makkah Council Of Health Insurance Saudi Health Council - Saudi Arabia Saudi Red Crescent Authority Saudi Central Board for Accreditation of Healthcare Institutions (CBAHI) Saudi Patient Safety Center - المركز السعودي لسلامة المرضى National Unified Procurement Company "NUPCO" تجمع الرياض الصحي الثالث تجمع الرياض الصحي الأول - Riyadh First Health Cluster تجمع الباحة الصحي تجمع حفرالباطن الصحي Hafar Al-Batin Health Cluster Riyadh Second Health Cluster تجمع الرياض الصحي الثاني تجمع الأحساء الصحي تجمع حائل الصحي Health Co. برنامج تحول القطاع الصحي | Health Sector Transformation Program (HSTP) Eastern Health Cluster | تجمع الشرقية الصحي

٩٥

٢ تعليق

Daily Critical Care Pearls #209: From the IVPN-Critical Care Listserv team, Review the Pharmacology of Analgesics used in the ICU using these amazingly designed Flashcards written by Dr. Jwan Basem and designed by Mai Gamal #criticalcare #clinicalpharmacy #medicine #pearls

٢٤٤

٤ تعليق

Syreon Middle East is at the forefront of health economics in the MENA region, contributing significantly to Health Technology Assessment (HTA) in Egypt. Through dedicated efforts, we have played a major role in HTA implementation, driving forward the country's healthcare system. Our commitment is reflected in the remarkable progress Egypt has achieved in HTA's milestones, paving the way for sustainable healthcare development: 1️) Capacity Building: We've spearheaded specialized training programs, including advanced individual patient simulation, budget impact analysis, and comprehensive one-year technical training. These initiatives elevate local expertise, ensuring HTA processes are rooted in a deep understanding of our healthcare landscape. 2️) Research & Publication: Our research endeavors have flourished, resulting in two influential papers on Multi-Criteria Decision Analysis (MCDA) for out-of-patent pharmaceuticals and medical devices, expanding the scope of HTA's impact. 3️) Decision-Making Criteria: We've launched two pivotal projects on cost-effectiveness analysis—one establishing the Cost-Effectiveness Threshold (CET) based on multipliers, and another tailored for orphan drugs, providing critical modifiers for decision-making in HTA. This journey represents only a fragment of our ongoing commitment to enhancing healthcare through robust economic evaluation and evidence-based decision-making. #SyreonMiddleEast #HTA #HealthcareEconomics #EgyptHealthcare #Innovation #PolicyMaking

١٠

SESSION HIGHLIGHT! PV Updates and Drug Safety Strategy, moderated by Dr. Ahmed H. from PVigilant Health, along with Dr. Hussain Talib Thani Al Ramimmy from Ministry of Health Oman, and DR. Dr. Reem Al-Essa from Ministry of Health Kuwait. What an informative session, rich with valuable presentations and Q and A with the audience. Stay tuned for more updates! #regulatoryaffairs #QPPV #pharmacuetical #Pharmacovigilance #UAE #PVTraining #PV #Training #pharmaregulations #GCCpharmacovigilanceTraining #GCC #pharma

٤١

The Department of Health Abu Dhabi (DoH) has inked a strategic partnership with Takeda Pharmaceuticals to advance research in rare diseases and #oncology. 🤝 This #MoU, signed in the presence of Mansoor Ibrahim Al Mansoori and key executives from both organizations, will bolster clinical research, innovation, and knowledge sharing to address healthcare gaps effectively. This partnership aims to leverage Abu Dhabi's advanced healthcare infrastructure and Takeda’s expertise in developing advanced therapies, driving innovation in healthcare technologies, and enhancing health technology assessment capabilities. 🔗Read More - https://lnkd.in/ddbJMCpC 🖊️Writes - Nikita Saha #Healthcare #Innovation #RareDiseases #Oncology #Research #DoH #Takeda #Partnership #HealthTech

٤